Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIXICON vs AMINOPHYLLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Management of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Treatment of acute bronchial asthma, reversible bronchospasm associated with chronic bronchitis and emphysema,Neonatal apnea (off-label),Adjunctive therapy in COPD exacerbations
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Primarily hepatic metabolism via cytochrome P450 1A2 (CYP1A2). Minor pathways include CYP2E1 and CYP3A4. Metabolites are excreted renally.
Hepatic demethylation and oxidation via cytochrome P450 isoenzymes (CYP1A2, CYP3A4, CYP2E1); approximately 10% excreted unchanged in urine.
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Approximately 40% bound, primarily to albumin.
~40% bound to plasma proteins (primarily albumin).
Vd: 0.3-0.5 L/kg; indicates distribution into total body water, minimal tissue binding.
0.5 L/kg (range 0.3–0.7 L/kg); increased in neonates, cirrhosis, and malnutrition; reflects distribution into total body water.
Oral immediate-release: 100%; Extended-release: 100% (well-absorbed, no first-pass metabolism).
Oral (immediate-release): 100% (well absorbed); rectal: ~80% (variable); IV: 100%.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and monitor theophylline levels; GFR < 10 m L/min: reduce dose by 50% and monitor levels.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25% and monitor levels; GFR <10 m L/min: reduce dose by 50% and monitor levels closely.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: use with extreme caution, reduce dose by 90% or consider alternative.
Initial: 5 mg/kg/dose orally every 6 hours; maintenance: 100-400 mg/day in divided doses; monitor levels aggressively.
Loading dose: 5-6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: infants <1 year: 0.4-0.7 mg/kg/hr IV; children 1-9 years: 0.8-1.0 mg/kg/hr IV; children >9 years: 0.6-0.8 mg/kg/hr IV. Oral: immediate-release 5 mg/kg every 6 hours; sustained-release not recommended under 6 years.
Start at lowest effective dose (e.g., 200 mg orally every 12 hours) due to reduced clearance; monitor theophylline levels and adjust based on response and tolerability.
Reduce maintenance dose by 50-75% compared to younger adults; monitor serum theophylline levels closely; typical starting maintenance: 0.3-0.5 mg/kg/hr IV; avoid doses >400 mg/day oral.
Theophylline has a narrow therapeutic index; plasma levels should be monitored to avoid toxicity. Dosage should be individualized based on steady-state serum concentrations. Concurrent illness, fever, or changes in smoking habits can alter theophylline clearance.
No specific FDA boxed warning for aminophylline; however, theophylline (its active metabolite) has a narrow therapeutic index and requires serum concentration monitoring to avoid toxicity.
Risk of seizures at high serum levels; may induce or worsen arrhythmias; use with caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders; drug interactions with cimetidine, fluoroquinolones, macrolides, and allopurinol can increase theophylline levels.
Narrow therapeutic index; monitor serum concentrations (target 10-20 mcg/m L); caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, cardiac arrhythmias; use with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, fluvoxamine) or induce metabolism (e.g., smoking, rifampin, phenytoin).
Hypersensitivity to theophylline or any component of the formulation; pre-existing cardiac arrhythmias (e.g., tachyarrhythmias); active seizure disorder.
Hypersensitivity to aminophylline, theophylline, or ethylenediamine; active peptic ulcer disease; uncontrolled seizure disorders; severe cardiac arrhythmias (unless patient is undergoing monitored treatment).
Avoid large amounts of caffeine-containing foods and beverages such as coffee, tea, cola, and chocolate as they may increase side effects like jitteriness and insomnia. High-fat meals may affect absorption; take consistently with respect to meals. Charcoal-broiled foods may increase metabolism of theophylline, reducing efficacy.
High-fat meals can delay absorption of aminophylline. Avoid charred meat and foods containing large amounts of caffeine. Cruciferous vegetables (broccoli, brussels sprouts) may increase metabolism. Maintain consistent dietary intake of protein and carbohydrates as changes can affect theophylline clearance.
Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly needed.
Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal asthma control benefits outweigh risks. Third trimester: Risk of neonatal apnea, irritability, and tachycardia if maternal levels are high; avoid toxic levels.
Excreted into breast milk; M/P ratio unknown. Caution advised, monitor infant for adverse effects.
Aminophylline is excreted into breast milk; the M/P ratio (milk-to-plasma ratio) is approximately 0.6-0.8. Infant exposure is low (about 1-10% of maternal weight-adjusted dose). Use with caution; monitor infant for irritability and sleep disturbance. Generally considered compatible with breastfeeding.
Increased clearance during pregnancy may require dose adjustment; monitor therapeutic levels.
Pregnancy reduces theophylline clearance by 30-50% due to decreased hepatic metabolism and increased volume of distribution. Dose adjustments may be needed: reduce dose by 30% in the third trimester or monitor serum concentrations closely to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; readjust accordingly.
ELIXICON (theophylline) requires therapeutic drug monitoring due to narrow therapeutic index of 10-20 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance. Cigarette smoking induces metabolism, requiring dose adjustments. Common side effects include nausea, vomiting, and insomnia; toxicity presents with tachycardia, seizures, or ventricular arrhythmias.
Aminophylline is a bronchodilator composed of theophylline and ethylenediamine. The ethylenediamine component can cause hypersensitivity reactions. Monitor theophylline serum levels (target 10-20 mcg/m L). Use with caution in patients with cardiac arrhythmias, seizures, or peptic ulcer disease. Avoid in patients with porphyria. Cimetidine, ciprofloxacin, and macrolides can increase theophylline levels. Smoking induces metabolism, requiring higher doses.
Take exactly as prescribed and do not change dose without consulting your doctor.,Avoid smoking and second-hand smoke as it affects how the medication works.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heart rate, or seizures.,Do not take this medication with other cold or asthma remedies without medical advice.
Take this medication exactly as prescribed, with or without food.,Do not crush or chew extended-release formulations.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, energy drinks) as it may increase side effects.,Report symptoms such as rapid heart rate, persistent nausea/vomiting, insomnia, or seizures immediately.,Do not stop abruptly without consulting your doctor.,Keep a regular dosing schedule to maintain consistent blood levels.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIXICON vs AMINOPHYLLIN, answered by our medical review team.
ELIXICON is a Xanthine Bronchodilator that works by Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.. AMINOPHYLLIN is a Xanthine Bronchodilator that works by Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIXICON and AMINOPHYLLIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIXICON is: 400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.. The standard adult dose of AMINOPHYLLIN is: Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIXICON and AMINOPHYLLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIXICON is classified as Category C. Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly n. AMINOPHYLLIN is classified as Category C. Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal ast. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.